This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jan-Erik Johansson, MD, PhD; Swen-Olof Andersson, MD
Örebro Medical Center Hospital

Hans-Olov Adami, MD, PhD; Lars Holmberg, MD
Uppsala University Sweden

JAMA. 1992;268(22):3199-3200.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We are well aware that our results challenge the value of a surgical procedure that many think is the treatment of choice, and that they are thus controversial.

Dr Catalona is eager to explain away the fact that we traced every incident case of the disease in a strictly defined area and subjected them to complete, extensive, and standardized long-term follow-up, which included measurements of serum acid phosphatase. He also fails to recognize that experimental methods need proper scientific assessment in clinical trials before they are implemented in general practice.

The present article and a previous one¹ show unequivocally that age at diagnosis is not an important determinant in our population of disease progression and death in prostate cancer. The age mix of the patients is therefore not an issue; individuals are followed until they die from intercurrent diseases and cannot further influence estimates of progression, relative . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?